1 Meier, JJ, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
2 Sorli, CH, Harashima, S-i, Tsoukas, GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre, phase 3a trial. Lancet Diabetes Endocrinol, 2017 published online Jan 16. http://dx.doi.org/10.1016/S2213-8587(17)30013-X.
3 Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
4 Moretto, TJ, Milton, DR, Ridge, TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30 (2008), 1448–1460.
5 Garber, A, Henry, R, Ratner, R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
6 Fonseca, VA, Alvarado-Ruiz, R, Raccah, D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35 (2012), 1225–1231.
7 Russell-Jones, D, Cuddihy, RM, Hanefeld, M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 (2012), 252–258.
8 Nauck, MA, Stewart, MW, Perkins, C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59 (2016), 266–274.
9 Umpierrez, G, Tofe Povedano, S, Perez Manghi, F, Shurzinske, L, Pechtner, V, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37 (2014), 2168–2176.
10 Scheen, AJ, Which incretin-based therapy for type 2 diabetes?. Lancet 384 (2014), 1325–1327.
11 Davies M, Pieber TR, Jabbour S, Hartoft-Nielsen M-L, Højbjerg Hansen OK, Rosenstock J. Dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes. Oral presentation at the 52nd annual meeting of the European Association for the Study of Diabetes, Munich, Germany; Sept 15, 2016, abstract 149.
